Sponsor or institution
Clinical trials and research at Anbogen Therapeutics, Inc.
As of November 12, 2026, Find a Trial lists 2 clinical trials run by Anbogen Therapeutics, Inc. that are recruiting, at sites in 2 countries (most in Taiwan (2), Australia (1)). By phase: Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer
This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.
-
Evaluating ABT-101 for patients with advanced solid tumors and non-small cell lung cancer
This study is testing a new drug called ABT-101 to see if it can help people with advanced solid tumors, especially those with certain mutations in non-small cell lung cancer.
Quick answers
How many clinical trials run by Anbogen Therapeutics, Inc. are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Taiwan (2 trials), Australia (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.